An interventional study of AEFIX External Fixation System and Standard of Care External Fixation System in Trauma (Including Fractures), Open Fracture of Tibia and Open Fracture, sponsored by Beth Israel Deaconess Medical Center. Not yet recruiting at 5 sites in Rwanda. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether AEFIX, a new low-cost external fixation system, works as well as the external fixators currently used in Rwandan public hospitals to hold broken thigh (femur) and shin (tibia) bones in position in adults. External fixation uses metal pins placed into the bone and connected by clamps and rods outside the body. It is commonly used for severe fractures, including open fractures, that cannot safely be treated with internal plates or rods right away.
The main questions it aims to answer are:
Researchers will compare AEFIX to the external fixation systems already used as standard care at each participating hospital to see whether AEFIX is no worse than these systems at keeping the bone in place.
Participants will:
About 150 adults will take part at up to five hospitals in Rwanda.
Background Musculoskeletal trauma is common and rising in Rwanda, driven largely by road traffic injuries, and open fractures of the tibia are among the most frequent and serious injuries treated at referral hospitals. External fixation is the standard of care for temporary, and sometimes definitive, stabilization of fractures that cannot safely undergo internal fixation because of infection risk, soft tissue injury, or patient instability. Industry-standard external fixator clamps cost approximately 500 USD each, which limits their availability in public hospitals in low- and middle-income countries, where many fixators in use are donated or reprocessed. AEFIX is an affordable modular external fixation system (approximately 15 USD per clamp) made from medical-grade hard coat anodized aluminum and stainless steel. Laboratory mechanical testing has shown performance comparable to industry-standard clamps. This trial evaluates whether AEFIX is non-inferior to locally available external fixation systems in routine clinical practice in Rwanda.
Design This is a multicenter, pragmatic, open-label, parallel-arm randomized controlled trial with a non-inferiority design. Eligible participants are randomized 1:1 in the operating theatre, after final confirmation of eligibility, using a centralized web-based randomization system. Participants in the comparator arm receive the external fixation system routinely used at the participating site. The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. Comparator systems at participating sites are predominantly Stryker Hoffmann 3. All participating surgeons complete a dedicated instructional course on the AEFIX technique before using the device.
Staged site activation Enrollment begins at the University Teaching Hospital of Kigali (CHUK) and the University Teaching Hospital of Butare (CHUB). Approximately the first 70 participants constitute an initial feasibility stage assessing recruitment rate (target of more than 3 participants per site per month), retention, and adherence to randomized allocation. Three district hospitals (Kabgayi, Kibagabaga, and Kibogora) will be activated following review of feasibility data by the independent Data and Safety Monitoring Committee (DSMC), or earlier if recruitment at CHUK and CHUB remains below target after three months of enrollment.
Sample size Assuming approximately 95% maintenance of fracture reduction in both arms, 74 participants (37 per arm) provide 90% power to demonstrate non-inferiority with a one-sided alpha of 0.05 and a non-inferiority margin of 15%. Allowing for up to 50% loss to follow-up, the trial will enroll 150 participants (75 per arm).
Statistical analysis The primary analysis follows the intention-to-treat principle and includes all comparator systems, reflecting routine practice. Per-protocol and as-treated analyses will assess robustness given the possibility of intraoperative device crossover. A pre-specified secondary analysis repeats the non-inferiority comparison among participants treated with AEFIX or Stryker Hoffmann 3, the predominant comparator, to provide a direct device-to-device comparison. Missing data will be handled by multiple imputation under a missing-at-random assumption, with sensitivity analyses. The trial biostatistician remains blinded to treatment allocation until database lock; the allocation key is held by an independent data manager with no role in outcome assessment or analysis.
Safety oversight An independent five-member DSMC with expertise in surgery, clinical research, research ethics, and biostatistics, based in Rwanda and the United States, meets quarterly and as needed. DSMC members have no financial relationship with the manufacturer of the investigational device or of the comparator devices. Causality of all adverse events is determined by the DSMC, independently of the study investigators and the device developer. Serious adverse device effects are reported to the Rwanda Food and Drugs Authority and the Rwanda National Research Ethics Committee in accordance with national requirements and ISO 14155:2020.
Conflict of interest The AEFIX device is developed and donated by SONA Global, a nonprofit organization founded by a study co-investigator, who receives no income, compensation, or equity from the organization.
2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.
This study's planned enrollment of 150 is above the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →Beth Israel Deaconess Medical Center is the lead sponsor of 570 studies on the registry; 81 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 62 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive fracture external fixation using the AEFIX system, an affordable modular external fixator consisting of AEFIX clamps (hard coat anodized aluminum), 11 mm aluminum connecting rods, and 5 mm Schanz pins. Components are steam sterilized on site before use. Pins are placed bicortically in anatomical safe zones and connected by clamps and rods in a unilateral double-rod or modular frame construct. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.
Device: AEFIX External Fixation System
Participants receive fracture external fixation using the locally available external fixation system routinely used as standard of care at the participating hospital, most commonly donated or reprocessed modular systems from established manufacturers (predominantly Stryker Hoffmann 3; also DePuy Synthes and others). The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.
Device: Standard of Care External Fixation System
Investigational modular external fixation system (clamps, connecting rods, and Schanz pins) designed for affordability in resource-limited settings. Clamps are made of medical-grade hard coat anodized aluminum and stainless steel, supplied non-sterile, and steam sterilized before single use. Manufactured by an ISO 13485-certified contract manufacturer for SONA Global.
Commercially available modular external fixation systems already in routine clinical use at participating hospitals, not supplied by the sponsor. Device brand, model, and reprocessing history are documented for each participant.
Loss of Fracture Reduction
Proportion of participants with loss of fracture reduction, defined as any of the following between the initial postoperative radiograph and the final radiograph before external fixator removal: angular deformity change greater than 5 degrees in the coronal or sagittal plane; translational displacement greater than 10 millimeters in any plane; or increase in fracture gap greater than 10 millimeters, measured using calibrated digital radiographic tools. Participants with more than one fracture treated with external fixation are counted as having loss of reduction if it occurs in any treated fracture. Non-inferiority of AEFIX relative to locally available external fixation systems is assessed using a pre-specified margin of 15% and a one-sided alpha of 0.05.
Time frame: From initial postoperative radiograph (within 24 hours of external fixator application) to final radiograph (within 48 hours before external fixator removal), up to 12 months
Number of Participants With Clinical Complications, by Type
Clinical complications include pin tract infection, superficial infection, deep infection, iatrogenic neurovascular injury, malunion, nonunion, amputation, and death, reported as the number of participants experiencing each complication per treatment arm.
Time frame: 6 weeks, 3 months, 6 months, and 12 months after initial surgery
Health-Related Quality of Life (EQ-5D-5L Index Score)
The EQ-5D-5L measures five dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels, and is summarized as an index score where 1 represents full health and 0 represents a state equivalent to death; values below 0 are possible. Higher scores indicate better health-related quality of life. A difference of 0.074 is considered the minimum clinically important difference.
Time frame: 6 weeks, 3 months, 6 months, and 12 months after initial surgery
Functional Fracture Healing (Functional IndeX for Trauma [FIX-IT] Score)
The FIX-IT score assesses ability to bear weight (0 to 6 points) and pain at the fracture site (0 to 6 points), for a total score ranging from 0 to 12. Higher scores indicate better clinical fracture healing and function. A change of 2 or more points is considered clinically meaningful.
Time frame: 6 weeks, 3 months, 6 months, and 12 months after initial surgery
Plan to share: Yes — De-identified individual participant data underlying the results reported in publications, including primary and secondary outcome data and baseline characteristics, will be made available to qualified researchers upon reasonable request. Data are owned by the University of Rwanda; sharing is subject to approval by the University of Rwanda and the Rwanda National Research Ethics Committee, compliance with Rwandan data protection law, and execution of a data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months after publication of the primary results and ending 5 years after publication.
Access criteria: Requests from qualified researchers with a methodologically sound proposal will be reviewed by the study investigators and the University of Rwanda. Approved requesters must sign a data use agreement prohibiting re-identification and limiting use to the approved proposal. Requests should be directed to the Principal Investigator.
Start is estimated for Dec 2026; primary completion for Mar 2029, 27 months later.
Of 546 non-industry interventional studies with no phase under Wounds and Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 27 months is above that.
Counting every sponsor, half of 599 studies reached it within 24 months; a quarter within 9 and three quarters within 48.
Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center →